MacroGenics, Inc. (MGNX), a Rockville, Maryland-based clinical-stage biopharmaceutical company, develops antibody-based cancer therapeutics. For this analysis, three current analyst price targets that can be individually attributed to a firm, analyst, and date were reviewed, rather than copying a single website's headline consensus. The targets span approximately $4 to $11, and their arithmetic mean is $7.00, rounded to $7 for the headline.
The dispersion is significant. B. Riley Securities analyst Mayank Mamtani upgraded the stock to Buy in April 2026 and later raised his target from $9 to $11 in August 2026. Barclays' Etzer Darout lifted his target from $4 to $6 in April 2026 and maintained an Overweight rating through late October 2026. Stifel Nicolaus, by contrast, reiterated a Hold with a $4 target in August 2026. Citigroup initiated coverage with a "Positive" rating in October 2026 but did not publish a numeric target, while TD Cowen and H.C. Wainwright hold ratings without current published targets. Weiss Ratings reiterated a sell-equivalent view in early November 2026. The gap between the $11 high and $4 low — nearly triple — captures genuine disagreement about whether the pipeline can translate clinical progress into durable value.
Shares recently closed near $2.42, toward the lower end of a 52-week range of roughly $1.32 to $5.08, with a market capitalization near $155 million. Reaching the $7 central target would require an advance of about 189%, a very large move by any standard, even for a volatile small-cap biotech. The company reported a quarterly profit of $0.31 per share in August 2026, beating expectations, but revenue of $32.83 million fell well short of the roughly $59 million analysts anticipated — a reminder that collaboration, milestone, and royalty income can be uneven. The stock lost roughly 38% in October 2026 after interim lorigerlimab data raised safety concerns, including severe side effects, underscoring how quickly clinical news can reset sentiment.
The most constructive case centers on the pipeline. MGC026, a B7-H3-targeting ADC, and MGC028, an ADAM9-targeting ADC, give the company exposure to one of oncology's most active drug classes, and positive interim data could justify a significant re-rating. Partnerships with larger firms, including Incyte, Gilead, and Sanofi, provide non-dilutive milestone potential. B. Riley's $11 target and Barclays' $6 Overweight reflect the view that the shares are undervalued relative to the optionality embedded in these programs. A favorable ADC or bispecific readout, new partnership economics, or a capital raise at a higher valuation would all be potential catalysts that could narrow the gap to the $7 level.
The principal obstacle is clinical and financial risk. The 2026 lorigerlimab safety data showed high rates of severe side effects, including a reported patient death, and a modest response rate that skeptics argue threatens the drug's competitive viability. Revenue remains lumpy and missed expectations in the latest quarter, while the company continues to burn cash as programs advance, raising the prospect of future equity dilution. Stifel's $4 Hold and the Weiss Ratings sell-equivalent call reflect this caution. Broader pressures — biotech sector rotation, higher-for-longer interest rates that compress valuations for pre-profit companies, and intense competition in ADC and bispecific development — could keep the shares below the target for an extended period.
The shares trade below both their 50-day and 200-day simple moving averages, near the $3.40–$3.50 zone, which now acts as overhead supply. The 52-week high near $5.08 is the next major resistance level, followed by psychological levels at $6 and the $11 high target. On the downside, the $2.00 area and the 52-week low near $1.32 are key support levels. Because the stock sits well beneath prior highs, any durable move toward $7 would first need to reclaim the moving averages and convert the $5 area from resistance into support.
Analyst price targets typically reflect a roughly 12-month research horizon, though the wide $4-to-$11 range shows that individual assumptions differ materially. Investors should watch upcoming clinical updates on MGC026, MGC028, and lorigerlimab, quarterly earnings and revenue recognition, any changes to partnership or milestone economics, cash runway disclosures, and analyst rating and target revisions. Regulatory and competitive developments in the ADC space could also shift sentiment quickly.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening. For investors following a volatile name like MGNX, automated signals can offer a useful complement to fundamental research — explore the signals to see how the AI reads current conditions.
The question of whether MacroGenics can reach $7 turns on whether its ADC and bispecific pipeline delivers data strong enough to overcome a recent safety-driven selloff and persistent cash burn. The $7 figure — the mean of three verified analyst targets spanning $4 to $11 — implies a roughly 189% move from recent levels, an ambitious but not unprecedented outcome for a small-cap biotech with active catalysts. Bullish analysts see undervalued optionality in MGC026 and MGC028; cautious ones weigh clinical toxicity, revenue volatility, and dilution. Neither path is assured, and the wide target dispersion itself signals genuine uncertainty. Investors should monitor clinical readouts, cash position, and analyst revisions rather than treat the $7 level as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | -1.29% | ||
| KRRO - MGNX | 45% Loosely correlated | -0.69% | ||
| AMRN - MGNX | 44% Loosely correlated | -0.34% | ||
| VYGR - MGNX | 42% Loosely correlated | -3.41% | ||
| ZVRA - MGNX | 39% Loosely correlated | -5.82% | ||
| MLTX - MGNX | 34% Loosely correlated | -4.74% | ||
More | ||||